Patents by Inventor Jong-Gu Park
Jong-Gu Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7148014Abstract: The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.Type: GrantFiled: August 13, 2003Date of Patent: December 12, 2006Assignee: University of PennsylvaniaInventors: Alan D. Schreiber, Jong-Gu Park
-
Patent number: 6756123Abstract: Disclosed is an anticorrosion paint for preventing steel materials from corrosion by using polyaniline as an anticorrosion pigment. The anticorrosion paint has an excellent anticorrosion effect, long persistence of the anticorrosion effect, high durability and superior coating property controlling the anticorrosion effect, without using metal causing environmental pollution as an anticorrosion pigment. Especially, in the anticorrosion paint, the top coat paint for improving the protection of the primer coat paint and the anticorrosion effect. The top coat paint includes 40 to 89 wt % of matrix resin, 5 to 54 wt % of colored pigment, 1 to 50 wt % of dopants and 5 to 54 wt % of mixed solvents, and the primer coat paint includes 3 to 49 wt % of the polyaniline, 40 to 86 wt % of the matrix resin, 1 to 47 wt % of the dopants and 10 to 56 wt % of the mixed solvents. The anticorrosion paint plays a role in exerting persistently the excellent anticorrosion effect without causing environmental problem.Type: GrantFiled: September 3, 2002Date of Patent: June 29, 2004Assignees: AD-Tech Co., Ltd., Samhwa Paints Ind. Co., Ltd.Inventors: Jae Mok Ha, Sung Nam Hwang, Jin Woo Park, Woo Jin Choi, Han Seob Song, Seong Kil Kim, Jong Gu Park, Yong Hee Lee, Yong Seok Park, Hong Soo Park
-
Publication number: 20040071677Abstract: The present application discloses a method of reducing inflammation in kidney of a subject, and includes treating nephritis and glomerulosclerosis, which method includes delivering to the kidney of the subject in need thereof a therapeutically effective amount of a gene encoding an anti-inflammatory or immunosuppressant protein. Gene encoding IL-10 is delivered to the kidney.Type: ApplicationFiled: August 5, 2003Publication date: April 15, 2004Inventors: Jong-Gu Park, Young-Kook Choi
-
Publication number: 20040048781Abstract: The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.Type: ApplicationFiled: August 13, 2003Publication date: March 11, 2004Applicant: THE UNIVERSITY OF PENNSYLVANIAInventors: Alan D. Schreiber, Jong-Gu Park
-
Publication number: 20040038280Abstract: Large circular (LC)-sense molecules in an array is disclosed. The LC-sense molecules array is combined with cDNA hybridization to detect differences in expression profile between different cells. LC-sense molecules were purified from nonredundant clones with recombinant phagemid and arrayed onto silanized slide glasses. By hybridization of LC-sense array with Cy3 or Cy5-labelled cDNA preparations at 60° C., 29 up-regulated and 6 down-regulated genes in cancerous liver tissue were detected.Type: ApplicationFiled: July 25, 2003Publication date: February 26, 2004Inventors: Jong-Gu Park, Yun-Han Lee
-
Publication number: 20040005464Abstract: Disclosed is an anticorrosion paint for preventing steel materials from corrosion by using polyaniline as an anticorrosion pigment. The anticorrosion paint has an excellent anticorrosion effect, long persistence of the anticorrosion effect, high durability and superior coating property controlling the anticorrosion effect, without using metal causing environmental pollution as an anticorrosion pigment. Especially, in the anticorrosion paint, the top coat paint for improving the protection of the primer coat paint and the anticorrosion effect. The top coat paint includes 40 to 89 wt % of matrix resin, 5 to 54 wt % of colored pigment, 1 to 50 wt % of dopants and 5 to 54 wt % of mixed solvents, and the primer coat paint includes 3 to 49 wt % of the polyaniline, 40 to 86 wt % of the matrix resin, 1 to 47 wt % of the dopants and 10 to 56 wt % of the mixed solvents. The anticorrosion paint plays a role in exerting persistently the excellent anticorrosion effect without causing environmental problem.Type: ApplicationFiled: September 3, 2002Publication date: January 8, 2004Applicants: AD-Tech Co., Ltd., Samhwa Paints Ind. Co., Ltd.Inventors: Jae Mok Ha, Sung Nam Hwang, Jin Woo Park, Woo Jin Choi, Han Seob Song, Seong Kil Kim, Jong Gu Park, Yong Hee Lee, Yong Seok Park, Hong Soo Park
-
Publication number: 20030216296Abstract: The present application discloses a transfection effective carrier polypeptide comprising derivatives of HIV Tat peptide.Type: ApplicationFiled: January 28, 2003Publication date: November 20, 2003Inventors: Jong-Gu Park, Ik-Jae Moon, Young-Cheol Kim
-
Patent number: 6638764Abstract: The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.Type: GrantFiled: March 20, 2001Date of Patent: October 28, 2003Assignee: University of PennsylvaniaInventors: Alan D. Schreiber, Jong-Gu Park
-
Publication number: 20030165892Abstract: The present invention provides a high throughput system for functional genomics using a unigene antisense library comprising LC-antisense compounds. The antisense compounds were specific and effective for the elimination of target mRNA. Thus, the system of the present invention is used as temporary knock-down system to unveil functions of genes critical for diseases. The system of the present invention can be adopted not only for functional genomics but also for effectively validating target for antisense or other molecular therapeutics against various malignancies, infections, and other diseases by blocking specific genes involved in the disease.Type: ApplicationFiled: May 15, 2002Publication date: September 4, 2003Applicant: WELGENE PHARMACEUTICALS, INC.Inventors: Jong-Gu Park, Ik-Jae Moon, Yun-Han Lee
-
Publication number: 20030153075Abstract: The present application describes a purified covalently closed antisense molecule, which specifically inhibits expression of TGF-&bgr;.Type: ApplicationFiled: December 30, 2002Publication date: August 14, 2003Inventors: Jong-Gu Park, Ik-Jae Moon, Young-Kook Choi, Kwankyu Park
-
Publication number: 20030130218Abstract: The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods.Type: ApplicationFiled: August 16, 2002Publication date: July 10, 2003Applicant: UNIVERSITY OF PENNSYLVANIAInventors: Alan D. Schreiber, Jong-Gu Park
-
Publication number: 20020182181Abstract: The present application describes a large circular target-specific antisense molecule that is effective in ablating RNA and protein expression. The large circular antisense molecule is used to treat any human disease in which modulation of gene expression can be beneficial to intervene in the disease initiation and progression.Type: ApplicationFiled: January 30, 2002Publication date: December 5, 2002Applicant: WELGENE, INC.Inventors: Jong-Gu Park, Ik-Jae Moon
-
Publication number: 20020168631Abstract: The present invention provides a high-throughput system for functional genomics using a random gene unidirectional antisense library comprising LC-antisense compounds. The antisense compounds were specific and effective for the elimination of target mRNA. Thus, the system of the present invention may be effectively used as temporary knock-down system to unveil functions of genes critical for diseases. The system of the present invention can be adapted not only for functional genomics but also for effectively validating target for antisense or other molecular therapeutics against various malignancies, infections, and other diseases by blocking specific genes involved in the disease.Type: ApplicationFiled: March 8, 2002Publication date: November 14, 2002Applicant: WELGENE, INC.Inventors: Jong-Gu Park, Ik-Jae Moon, Yun-Han Lee
-
Patent number: 6475997Abstract: The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods.Type: GrantFiled: June 14, 1999Date of Patent: November 5, 2002Assignee: University of PennsylvaniaInventors: Alan D. Schreiber, Jong-Gu Park
-
Publication number: 20020068703Abstract: The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.Type: ApplicationFiled: March 20, 2001Publication date: June 6, 2002Applicant: UNIVERSITY OF PENNSYLVANIA.Inventors: Alan D. Schreiber, Jong-Gu Park
-
Patent number: 6242427Abstract: The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.Type: GrantFiled: September 14, 1998Date of Patent: June 5, 2001Assignee: University of PennsylvaniaInventors: Alan D. Schreiber, Jong-Gu Park
-
Patent number: 6068983Abstract: The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods.Type: GrantFiled: July 30, 1997Date of Patent: May 30, 2000Assignee: University of PennsylvaniaInventors: Alan D. Schreiber, Jong-Gu Park
-
Patent number: 5858981Abstract: The present invention relates, in general, to methods of treating diseases resulting from interactions between immune complexes and Fc receptors. In particular, the present invention relates to methods of modulating the clearance of antibody-coated cells from the circulation by inhibiting phagocytosis and to methods of modulating the interaction of immune complexes with tissue Fc receptors. Further, the invention relates to methods of modulating the activation of immunological processes mediated by Fc receptor activation resulting from antibody-antigen/receptor interaction.Type: GrantFiled: June 7, 1996Date of Patent: January 12, 1999Assignee: University of PennsylvaniaInventors: Alan D. Schreiber, Jong-Gu Park
-
Patent number: 5821071Abstract: The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods.Type: GrantFiled: September 30, 1994Date of Patent: October 13, 1998Assignee: University of PennsylvaniaInventors: Alan D. Schreiber, Jong-Gu Park
-
Patent number: 5776910Abstract: The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods.Type: GrantFiled: June 6, 1995Date of Patent: July 7, 1998Assignee: University of PennsylvaniaInventors: Alan D. Schreiber, Jong-Gu Park